FDA Green-lights Casio’s DZ-D100 Dermocamera and the DZ-S50 Scope

The DZ-D100 and DZ-S50 will be available in the U.S. on Casio America's e-commerce site by March 2022.

The U.S. Food and Drug Administration (FDA) has cleared Casio’s DZ-D100 Dermocamera  and the DZ-S50 scope for skin observation as medical devices. 

The DZ-D100 and DZ-S50 will be available in the U.S. on Casio America's e-commerce site by March 2022.

 Casio began providing the DZ-D100 in Japan in May 2019. The DZ-D100 was developed in collaboration with dermatology professionals and delivers both standard sized and close-up shots of an affected area with a single unit, and can be used with the D'z Image Viewer, a free downloadable software to manage the captured images. 

In March 2020, Casio released the DZ-S50 scope, making skin observation even easier. These Casio products make it simple to take both ordinary or standard sized and close-up shots without switching lenses and can capture polarized, non-polarized and UV photos at the same viewpoint with a single click of the shutter button. 

Casio has been rolling out these devices in markets outside Japan, starting with the launch in Australia and New Zealand in February 2021, where there are high rates of skin disease among the population. 

The marketing of certain medical devices in the U.S. requires FDA clearance. The DZ-D100 and DZ-S50 have received FDA Class I clearance. Class I medical devices are devices with low or moderate risk to patient health and safety.